Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

3.3K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.3K
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

680
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
680
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

1.8K
Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
1.8K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

747
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
747
Pneumonia IV: Management01:28

Pneumonia IV: Management

709
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
709
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

2.4K
The pathophysiology of pneumonia involves the following steps:
2.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Blinatumomab Consolidation for High-Risk Ph-negative B-cell Acute Lymphoblastic Leukemia: the GRAALL-2014/B-QUEST Study.

Blood·2026
Same author

Outcomes of 544 Patients with t(6;9)/DEK::NUP214 acute myeloid leukemia undergoing allogeneic stem cell transplantation: an EBMT study on behalf of the acute leukemia working party (ALWP) and the pediatric diseases working party (PDWP).

Bone marrow transplantation·2026
Same author

Impact of stem cell source in HLA-matched hematopoietic stem cell transplant for acute lymphoblastic leukemia in first complete remission: a study from the GRAALL and the SFGM-TC.

Bone marrow transplantation·2026
Same author

Use of Maribavir in Adult Patients With Post-Transplant Refractory Cytomegalovirus Infection in the Real-Life Setting.

Transplant international : official journal of the European Society for Organ Transplantation·2026
Same author

Length of SARS-CoV-2 shedding in HCT recipients: an Infectious Disease Working Party of EBMT study.

Bone marrow transplantation·2026
Same author

Lessons derived from a 3-year congenital cytomegalovirus screening programme in Israel: a prospective population-based cohort study.

The Lancet. Infectious diseases·2025
Same journal

Projected health and economic impact of PCV20 vaccination in UK children: a dynamic transmission model.

Expert review of vaccines·2026
Same journal

Evaluating the societal value of adult respiratory vaccination in Sweden: a benefit-cost analysis.

Expert review of vaccines·2026
Same journal

Evaluating the socioeconomic value of adult respiratory immunization in Spain: a benefit-cost analysis.

Expert review of vaccines·2026
Same journal

Whole cell and acellular pertussis vaccines - rethinking the evidence.

Expert review of vaccines·2026
Same journal

Modeling the potential public health and economic impact and cost-effectiveness of vaccination strategies using an adapted COVID-19 vaccine in the Dominican Republic.

Expert review of vaccines·2026
Same journal

Narrative shielding and prebunking: a synergistic strategy against vaccine hesitancy in pediatrics.

Expert review of vaccines·2026
See all related articles

Related Experiment Video

Updated: Jan 5, 2026

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
12:21

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness

Published on: September 28, 2022

3.0K

Pneumococcal immunization in immunocompromised hosts: where do we stand?

Catherine Cordonnier1, Diana Averbuch, Sébastien Maury

  • 1Hematology Department, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP) and Université Paris-Est-Créteil, Créteil 94000, France.

Expert Review of Vaccines
|December 7, 2013
PubMed
Summary
This summary is machine-generated.

Immunocompromised patients face risks from pneumococcal disease. While polysaccharide vaccines show limited efficacy, conjugate vaccines offer improved immunogenicity and a better response in these vulnerable populations.

More Related Videos

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.5K
Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

16.1K

Related Experiment Videos

Last Updated: Jan 5, 2026

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
12:21

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness

Published on: September 28, 2022

3.0K
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.5K
Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

16.1K

Area of Science:

  • Immunology
  • Vaccinology
  • Infectious Diseases

Background:

  • Immunocompromised patients are at high risk for invasive pneumococcal disease.
  • Pneumococcal immunization has advanced, but efficacy in immunocompromised individuals remains a concern.
  • The 23-valent polysaccharide vaccine demonstrates sub-optimal immunogenicity and efficacy in these populations.

Purpose of the Study:

  • To review the efficacy and safety of antipneumococcal vaccines in immunocompromised patients.
  • To critically appraise current guidelines for pneumococcal immunization in cancer, transplant, and HIV-positive patients.
  • To compare polysaccharide and conjugate vaccine performance in immunocompromised populations.

Main Methods:

  • Systematic review of existing literature on antipneumococcal vaccine efficacy and safety.
  • Analysis of clinical trial data for polysaccharide and conjugate vaccines.
  • Evaluation of vaccine immunogenicity and T-cell dependent responses.

Main Results:

  • The 23-valent polysaccharide vaccine has shown low immunogenicity and efficacy in immunocompromised patients.
  • Conjugate vaccines, like the 7-valent pneumococcal conjugate vaccine, demonstrate improved immunogenicity and T-cell dependent responses.
  • Conjugate vaccines offer a better early response and boost effect compared to polysaccharide vaccines.

Conclusions:

  • Conjugate vaccines represent a significant advancement over polysaccharide vaccines for immunocompromised patients.
  • Further evaluation and optimization of pneumococcal immunization strategies are needed for cancer, transplant, and HIV-positive individuals.
  • Current guidelines require critical appraisal in light of newer conjugate vaccine data.